BR9509269A - Processo para tratar diabetes - Google Patents
Processo para tratar diabetesInfo
- Publication number
- BR9509269A BR9509269A BR9509269A BR9509269A BR9509269A BR 9509269 A BR9509269 A BR 9509269A BR 9509269 A BR9509269 A BR 9509269A BR 9509269 A BR9509269 A BR 9509269A BR 9509269 A BR9509269 A BR 9509269A
- Authority
- BR
- Brazil
- Prior art keywords
- treat diabetes
- diabetes
- treat
- mammals
- pharmaceutical compositions
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32334094A | 1994-10-13 | 1994-10-13 | |
| US32347594A | 1994-10-13 | 1994-10-13 | |
| US48782595A | 1995-06-07 | 1995-06-07 | |
| PCT/IB1995/000992 WO1996011950A1 (en) | 1994-10-13 | 1995-10-12 | Method of treating diabetes mellitus using kgf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9509269A true BR9509269A (pt) | 1997-12-23 |
Family
ID=27406268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9509329A BR9509329A (pt) | 1994-10-13 | 1995-10-12 | Análogo de polipeptideo formulação farmacéutica molécula de ácido nucleico vetor viral ou plasmídeo biologicamente funcional célula hospedeira procariótica ou eucariótica processos para a produção de um análogo de polipeptideo de kgf e processo para estimular a produção de células epiteliais não fibroblastos |
| BR9509269A BR9509269A (pt) | 1994-10-13 | 1995-10-12 | Processo para tratar diabetes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9509329A BR9509329A (pt) | 1994-10-13 | 1995-10-12 | Análogo de polipeptideo formulação farmacéutica molécula de ácido nucleico vetor viral ou plasmídeo biologicamente funcional célula hospedeira procariótica ou eucariótica processos para a produção de um análogo de polipeptideo de kgf e processo para estimular a produção de células epiteliais não fibroblastos |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP0785948B1 (pt) |
| JP (2) | JP4216329B2 (pt) |
| KR (1) | KR100278597B1 (pt) |
| CN (1) | CN1168678A (pt) |
| AT (2) | ATE237633T1 (pt) |
| AU (1) | AU3707795A (pt) |
| BG (2) | BG101392A (pt) |
| BR (2) | BR9509329A (pt) |
| CA (2) | CA2202075C (pt) |
| CZ (3) | CZ98197A3 (pt) |
| DE (2) | DE69535264T2 (pt) |
| DK (2) | DK0785948T3 (pt) |
| EE (2) | EE03975B1 (pt) |
| ES (2) | ES2196082T3 (pt) |
| FI (2) | FI971420A0 (pt) |
| HU (2) | HUT78050A (pt) |
| NO (2) | NO318761B1 (pt) |
| NZ (2) | NZ505502A (pt) |
| PL (2) | PL182888B1 (pt) |
| PT (2) | PT804479E (pt) |
| SI (2) | SI0804479T1 (pt) |
| SK (2) | SK284534B6 (pt) |
| WO (2) | WO1996011949A2 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2153816T3 (es) | 1989-01-31 | 2001-03-16 | Jeffrey S Rubin | Adn que codifica un factor de crecimiento especifico contra celulas epiteliales. |
| BR9407035A (pt) | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
| US7084119B2 (en) | 1993-06-29 | 2006-08-01 | Chiron Corporation | Truncated keratinocyte growth factor (KGF) having increased biological activity |
| ES2197926T3 (es) * | 1994-10-13 | 2004-01-16 | Amgen Inc. | Metodo para purificar factores de crecimiento de queratinocitos. |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| DK0822943T3 (da) * | 1995-04-27 | 1999-11-29 | Cooperatie Cosun U A | Inulinderivater |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| ES2218666T3 (es) * | 1996-10-15 | 2004-11-16 | Amgen Inc., | Producto a base del factor de crecimiento de queratinocitos-2 (kggf-2). |
| EP1473366A1 (en) * | 1996-10-15 | 2004-11-03 | Amgen Inc. | Keratinocyte growth factor-2 products |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| AU751898B2 (en) | 1997-07-14 | 2002-08-29 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| KR20010033484A (ko) | 1997-12-22 | 2001-04-25 | 휴먼 게놈 사이언시즈, 인크. | 각질세포 성장 인자-2 제제 |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| US6242666B1 (en) | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| KR100731826B1 (ko) * | 1999-01-14 | 2007-06-22 | 볼더 바이오테크놀로지 인코퍼레이티드 | 유리 시스테인 잔기를 함유하는 단백질의 제조 방법 |
| US6248725B1 (en) | 1999-02-23 | 2001-06-19 | Amgen, Inc. | Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction |
| KR20030074791A (ko) * | 2001-02-06 | 2003-09-19 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질 각질세포성장인자(kgf) |
| AU2007214362B2 (en) * | 2001-08-21 | 2009-11-26 | Novartis Vaccines And Diagnostics, Inc. | KGF polypeptide compositions |
| MXPA04001526A (es) | 2001-08-21 | 2004-05-31 | Chiron Corp | Composiciones de polipetidos kgf. |
| PL1827483T3 (pl) | 2004-12-15 | 2014-12-31 | Swedish Orphan Biovitrum Ab Publ | Formulacje terapeutyczne czynnika wzrostu keratynocytów |
| CN102242124B (zh) * | 2010-05-10 | 2013-05-22 | 齐鲁制药有限公司 | 改造的角化细胞生长因子基因及其在酵母中的表达 |
| KR102440312B1 (ko) * | 2020-08-28 | 2022-09-05 | 한국해양과학기술원 | 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| JPH01137994A (ja) * | 1987-08-10 | 1989-05-30 | Shionogi & Co Ltd | reg蛋白質 |
| US5145225A (en) * | 1988-07-27 | 1992-09-08 | Muller George M | Carpet stretcher |
| ES2153816T3 (es) * | 1989-01-31 | 2001-03-16 | Jeffrey S Rubin | Adn que codifica un factor de crecimiento especifico contra celulas epiteliales. |
| JP3303211B2 (ja) * | 1991-04-26 | 2002-07-15 | 武田薬品工業株式会社 | bFGFムテインおよびその製造法 |
| UA46706C2 (uk) * | 1993-03-26 | 2002-06-17 | Амген Інк. | Спосіб лікування та запобігання хворобливому стану пацієнта, фармацевтична композиція |
| US5348563A (en) * | 1993-06-29 | 1994-09-20 | Honeywell Inc. | Air purifying apparatus |
| BR9407035A (pt) * | 1993-06-29 | 1996-03-12 | Chiron Corp | Fragmento de fator de crescimento de queratinócitos conjugado composição terapêutica molécula de DNA vetor de expressão célula hospedeira processo para produzir fragmento de fator de crescimento de queratinócitos processo para cicatrização de ferimento e processo de tratamento de doença hiperproliferativa da epiderme |
| GB9315501D0 (en) * | 1993-07-27 | 1993-09-08 | Ici Plc | Surfactant compositions |
| AU7475694A (en) * | 1993-08-02 | 1995-02-28 | Prizm Pharmaceuticals, Inc. | Monogenous preparations of cytotoxic conjugates |
-
1995
- 1995-10-12 AT AT95934793T patent/ATE237633T1/de active
- 1995-10-12 EE EE9700081A patent/EE03975B1/xx not_active IP Right Cessation
- 1995-10-12 CA CA002202075A patent/CA2202075C/en not_active Expired - Fee Related
- 1995-10-12 JP JP51307796A patent/JP4216329B2/ja not_active Expired - Fee Related
- 1995-10-12 SI SI9530728T patent/SI0804479T1/sl unknown
- 1995-10-12 SI SI9530654T patent/SI0785948T1/xx unknown
- 1995-10-12 ES ES95934793T patent/ES2196082T3/es not_active Expired - Lifetime
- 1995-10-12 DE DE69535264T patent/DE69535264T2/de not_active Expired - Lifetime
- 1995-10-12 CZ CZ97981A patent/CZ98197A3/cs unknown
- 1995-10-12 SK SK455-97A patent/SK284534B6/sk not_active IP Right Cessation
- 1995-10-12 AT AT95934808T patent/ATE342278T1/de active
- 1995-10-12 DE DE69530403T patent/DE69530403T2/de not_active Expired - Lifetime
- 1995-10-12 WO PCT/IB1995/000971 patent/WO1996011949A2/en not_active Ceased
- 1995-10-12 EP EP95934793A patent/EP0785948B1/en not_active Expired - Lifetime
- 1995-10-12 DK DK95934793T patent/DK0785948T3/da active
- 1995-10-12 EE EE9700225A patent/EE9700225A/xx unknown
- 1995-10-12 PT PT95934808T patent/PT804479E/pt unknown
- 1995-10-12 DK DK95934808T patent/DK0804479T3/da active
- 1995-10-12 HU HU9901071A patent/HUT78050A/hu unknown
- 1995-10-12 EP EP95934808A patent/EP0804479B1/en not_active Expired - Lifetime
- 1995-10-12 BR BR9509329A patent/BR9509329A/pt not_active Application Discontinuation
- 1995-10-12 PL PL95319784A patent/PL182888B1/pl not_active IP Right Cessation
- 1995-10-12 CZ CZ0105097A patent/CZ297328B6/cs not_active IP Right Cessation
- 1995-10-12 CZ CZ20023953A patent/CZ297329B6/cs not_active IP Right Cessation
- 1995-10-12 JP JP51307696A patent/JP4426646B2/ja not_active Expired - Fee Related
- 1995-10-12 PL PL95320484A patent/PL320484A1/xx unknown
- 1995-10-12 PT PT95934793T patent/PT785948E/pt unknown
- 1995-10-12 SK SK431-97A patent/SK43197A3/sk unknown
- 1995-10-12 KR KR1019970702343A patent/KR100278597B1/ko not_active Expired - Fee Related
- 1995-10-12 CA CA002201940A patent/CA2201940C/en not_active Expired - Fee Related
- 1995-10-12 ES ES95934808T patent/ES2273338T3/es not_active Expired - Lifetime
- 1995-10-12 HU HU9901255A patent/HU226168B1/hu not_active IP Right Cessation
- 1995-10-12 WO PCT/IB1995/000992 patent/WO1996011950A1/en not_active Ceased
- 1995-10-12 NZ NZ505502A patent/NZ505502A/en not_active IP Right Cessation
- 1995-10-12 BR BR9509269A patent/BR9509269A/pt not_active Application Discontinuation
- 1995-10-12 FI FI971420A patent/FI971420A0/fi unknown
- 1995-10-12 CN CN95196410A patent/CN1168678A/zh active Pending
- 1995-10-12 AU AU37077/95A patent/AU3707795A/en not_active Abandoned
-
1997
- 1997-04-04 NO NO19971568A patent/NO318761B1/no not_active IP Right Cessation
- 1997-04-04 NO NO971566A patent/NO971566L/no unknown
- 1997-04-07 BG BG101392A patent/BG101392A/xx unknown
- 1997-04-11 BG BG101408A patent/BG63167B1/bg unknown
- 1997-04-11 FI FI971536A patent/FI120040B/fi not_active IP Right Cessation
-
1999
- 1999-04-09 NZ NZ335109A patent/NZ335109A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9509269A (pt) | Processo para tratar diabetes | |
| BR8907538A (pt) | Processo e composicao de tecido para enxertos | |
| BR8804098A (pt) | Compostos,composicoes e processo para reducao da fitotoxidez de plantas de cultura | |
| DE59807213D1 (de) | 11beta-halogen-7alpha-substituierte-estratriene, verfahren zur herstellung pharmazeutischer präparate, die diese 11beta-halogen-7alpha-substituierte-estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln | |
| BR9608638A (pt) | Processo e composição farmacêutica para o tratamento seletivo do crescimento e diferenciação de células e composto | |
| FI960949L (fi) | Uusi lipaasi, lipaasia tuottavat mikro-organismit, menetelmä lipaasin tuottamiseksi ja lipaasin käyttö | |
| DE69434937D1 (de) | Verfahren zur Herstellung von Leistungsbauteilen in MOS-Technologie | |
| ES2081488T3 (es) | Uso de fosfolipido en la fabricacion de un medicamento topico para modificar los niveles de colesterol serico. | |
| BR9100046A (pt) | Derivados de azaoxindole,composicao farmaceutica e processo para o tratamento de mamiferos | |
| BR8502985A (pt) | Composicao e processo para o tratamento de solo | |
| MX9302951A (es) | Composicion farmaceutica para tratar la hiperproliferacion celular. | |
| ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| BR9711104B1 (pt) | processo para preparar uma composição polidispersada de sacarìdeos, composição polidispersada de sacarìdeos e produto compreendendo uma composição polidispersada de sacarìdeos. | |
| BR8107035A (pt) | Composicoes de cura anaerobia e processo para ligacao de superficies | |
| BR9300034A (pt) | Composto,processo para sua producao e composicao curavel | |
| BR8803768A (pt) | Composicao odorante,processo para producao de compostos e uso dos ditos compostos | |
| DE59606567D1 (de) | Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren | |
| FI944826L (fi) | Menetelmä selluloosamateriaalin käsittelemiseksi ja menetelmässä käyttökelpoisia koostumuksia | |
| BR9500886A (pt) | Composições com efeito regulador de crescimento e método para o tratamento de culturas | |
| ES2163001T3 (es) | Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica. | |
| DE69618340D1 (de) | Verfahren zur herstellung von substituierten anthrachinonen und deren verwendung zur herstellung von rheinen | |
| FI940496A0 (fi) | Esijännittyvä ruuvi ja menetelmä esijännityksen toteuttamiseksi | |
| BR9501945A (pt) | Composto processo composições farmacêuticas uso e processo para tratamento de mamíferos | |
| BR8904720A (pt) | Composicao e processo para tratamento de tecidos | |
| FI956064A0 (fi) | Menetelmä haavojen paranemisen edistämiseksi ja tähän soveltuvia koostumuksia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| FC | Decision: refusal |